{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:50:00Z","timestamp":1790621400336,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40261-018-0688-3","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T06:41:01Z","timestamp":1536216061000},"page":"955-965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy"],"prefix":"10.1007","volume":"38","author":[{"given":"Raffaella","family":"Viti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3974-3798","authenticated-orcid":false,"given":"Andrea","family":"Marcellusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Marasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Saverio","family":"Mennini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"issue":"6","key":"688_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00431-011-1474-x","volume":"170","author":"G Driessen","year":"2011","unstructured":"Driessen G, van der Burg M. Educational paper: primary antibody deficiencies. Eur J Pediatr. 2011;170(6):693\u2013702.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"688_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10875-013-9975-1","volume":"34","author":"JS Stonebraker","year":"2014","unstructured":"Stonebraker JS, et al. Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin. J Clin Immunol. 2014;34(2):233\u201344.","journal-title":"J Clin Immunol"},{"issue":"Suppl 1","key":"688_CR3","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.tmrv.2009.09.011","volume":"24","author":"N Shehata","year":"2010","unstructured":"Shehata N, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev. 2010;24(Suppl 1):S28\u201350.","journal-title":"Transfus Med Rev"},{"key":"688_CR4","first-page":"28","volume":"5","author":"IB Quinti","year":"2013","unstructured":"Quinti IB, Barilaro G. Le immunoglobuline per uso endovenoso: efficacia, tollerabilit\u00e0 e consumo. Rivista di Immunologia e Allergologia Pediatrica. 2013;5:28\u201336.","journal-title":"Rivista di Immunologia e Allergologia Pediatrica."},{"key":"688_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3389\/fimmu.2014.00629","volume":"5","author":"J Kerr","year":"2014","unstructured":"Kerr J, et al. Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Front Immunol. 2014;5:629.","journal-title":"Front Immunol."},{"key":"688_CR6","unstructured":"European Primary Immunodeficiencies Consensus Conference, Consensus Report and Recommendations, in European Primary Immunodeficiencies Consensus Conference. 19\u201320 June 2006: Paul-Ehrlich-Institut, Langen, Germany."},{"issue":"1","key":"688_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2004.02.002","volume":"112","author":"M Berger","year":"2004","unstructured":"Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112(1):1\u20137.","journal-title":"Clin Immunol."},{"issue":"4","key":"688_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.iac.2008.07.002","volume":"28","author":"Melvin Berger","year":"2008","unstructured":"Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am. 2008;28(4):779\u2013802, viii.","journal-title":"Immunology and Allergy Clinics of North America"},{"issue":"6","key":"688_CR9","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.jaci.2008.08.033","volume":"122","author":"FA Bonilla","year":"2008","unstructured":"Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol. 2008;122(6):1238\u20139.","journal-title":"J Allergy Clin Immunol."},{"issue":"Suppl 1","key":"688_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/cei.12519","volume":"178","author":"RL Wasserman","year":"2014","unstructured":"Wasserman RL. Subcutaneous immunoglobulin: facilitated infusion and advances in administration. Clin Exp Immunol. 2014;178(Suppl 1):75\u20137.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"688_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF03320711","volume":"1","author":"A Matucci","year":"2008","unstructured":"Matucci A, et al. Analisi di minimizzazione dei costi della terapia con Immunoglobuline (Ig) per il trattamento di pazienti con immunodeficienza primaria: confronto tra terapia con Ig sottocute vs endovena. Giornale Italiano di Health Technology Assessment. 2008;1(1):31\u20137.","journal-title":"Giornale Italiano di Health Technology Assessment."},{"issue":"Suppl 1","key":"688_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/cei.12496","volume":"178","author":"B Grimbacher","year":"2014","unstructured":"Grimbacher B. ESID Registry Working Party, The European Society for Immunodeficiencies (ESID) registry 2014. Clin Exp Immunol. 2014;178(Suppl 1):18\u201320.","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"688_CR13","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","volume":"119","author":"A Angelis","year":"2015","unstructured":"Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119(7):964\u201379.","journal-title":"Health Policy"},{"key":"688_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1750-1172-9-37","volume":"9","author":"M Mazzucato","year":"2014","unstructured":"Mazzucato M, et al. A population-based registry as a source of health indicators for rare diseases: the ten-year experience of the Veneto Region\u2019s rare diseases registry. Orphanet J Rare Dis. 2014;9:37.","journal-title":"Orphanet J Rare Dis."},{"issue":"3","key":"688_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2307\/3349801","volume":"60","author":"TA Hodgson","year":"1982","unstructured":"Hodgson TA, Meiners MR. Cost of illness methodology: a guide to current practices and procedures. Milbank Memor Fund Q. 1982;60(3):429\u201362.","journal-title":"Milbank Memor Fund Q."},{"key":"688_CR16","first-page":"43","volume-title":"Health care cost, quality, and outcomes: ISPOR book of terms","author":"ML Berger","year":"2003","unstructured":"Berger ML, et al. Cost of Illness Study. In: Bingefors K, Pashos CL, Dix Smith M, Berger ML, Hedblom EC, Torrance GW, editors. Health care cost, quality, and outcomes: ISPOR book of terms. Lawrenceville: ISPOR; 2003. p. 43\u20134."},{"key":"688_CR17","unstructured":"Segel JE. Cost-of-illness studies\u2014a primer. RTI-UNC Center of Excellence in Health Promotion Economics; 2006."},{"key":"688_CR18","unstructured":"Green S, Higgins J. Cochrane handbook for systematic reviews of interventions 4.2.5. The Cochrane Collaboration 2005. 19 May 2009. http:\/\/www.cochrane.org\/resources\/glossary.htm . Accessed 31 Jul 2018."},{"issue":"7","key":"688_CR19","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA STATEMENT. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med."},{"key":"688_CR20","doi-asserted-by":"crossref","unstructured":"CEREDIH: The French PID Study Group. The French national registry of primary immunodeficiency diseases. Clin Immunol. 2010;135(2):264\u201372.","DOI":"10.1016\/j.clim.2010.02.021"},{"issue":"1","key":"688_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/cei.12172","volume":"175","author":"JD Edgar","year":"2014","unstructured":"Edgar JD, et al. The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4\u00a0years\u2019 activity 2008-2012. Clin Exp Immunol. 2014;175(1):68\u201378.","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"688_CR22","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s10875-014-0102-8","volume":"34","author":"L Kobrynski","year":"2014","unstructured":"Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001\u20132007. J Clin Immunol. 2014;34(8):954\u201361.","journal-title":"J Clin Immunol"},{"issue":"Suppl 1","key":"688_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2249.2009.03954.x","volume":"157","author":"B Gathmann","year":"2009","unstructured":"Gathmann B, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol. 2009;157(Suppl 1):3\u201311.","journal-title":"Clin Exp Immunol"},{"key":"688_CR24","unstructured":"Calizzani G, et al. Analisi della domanda dei principali medicinali plasmaderivati in Italia. Anni 2007\u20132011. Rapporto ISTISAN 2012, Isituto Superiore di Sanit\u00e0. p. 167."},{"issue":"3","key":"688_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10875-011-9511-0","volume":"31","author":"I Quinti","year":"2011","unstructured":"Quinti I, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011;31(3):315\u201322.","journal-title":"J Clin Immunol"},{"key":"688_CR26","unstructured":"Istituto Nazionale di Statistica. Rivalutazione e documentazione su prezzi, costi e retribuzioni contrattuali. Indice dei prezzi al consumo per famiglie operai e impiegati. Novembre 2013. http:\/\/rivaluta.istat.it\/ . Accessed 31 Jul 2018."},{"key":"688_CR27","unstructured":"Gazzetta Ufficiale della Repubblica Italiana. Regime di rimborsabilit\u00e0 e prezzo di vendita di nuove confezioni dei medicinali. 2015. http:\/\/www.gazzettaufficiale.it . Accessed 31 Jul 2018."},{"key":"688_CR28","unstructured":"Farmadati Italia. Banca Dati Online [cited May 2016]. http:\/\/www.farmadati.it\/default.aspx . Accessed 31 Jul 2018."},{"issue":"6","key":"688_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jaip.2013.09.012","volume":"1","author":"M Berger","year":"2013","unstructured":"Berger M. Adverse effects of IgG therapy. J Allergy Clin Immunol Pract. 2013;1(6):558\u201366.","journal-title":"J Allergy Clin Immunol Pract."},{"key":"688_CR30","unstructured":"EUROSTAT. Hourly labour costs by NACE Rev. 1.1 activity. 2004. http:\/\/appsso.eurostat.ec.europa.eu\/nui\/show.do?dataset=lc_an_costh&lang=en . Accessed 31 Jul 2018."},{"key":"688_CR31","doi-asserted-by":"crossref","unstructured":"Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York; O.U.P. Inc.; 2007.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"issue":"23","key":"688_CR32","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1001\/jama.289.23.3135","volume":"289","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, et al. Cost of lost productive work time among US workers with depression. JAMA. 2003;289(23):3135\u201344.","journal-title":"JAMA"},{"key":"688_CR33","unstructured":"Hemp P. Presenteeism: at work\u2014but out of it. Harv Bus Rev. 2004;82(10):49\u201358, 155."},{"issue":"5","key":"688_CR34","first-page":"e102","volume":"167","author":"A Capone","year":"2016","unstructured":"Capone A, et al. Health Data Entanglement and artificial intelligence-based analysis: a brand new methodology to improve the effectiveness of healthcare services. Clin Ter. 2016;167(5):e102\u201311.","journal-title":"Clin Ter"},{"issue":"4","key":"688_CR35","first-page":"25","volume":"1","author":"N Mahlaoui","year":"2014","unstructured":"Mahlaoui N, et al. The European Society for Immunodeficiencies (ESID) Registry: recent advancements in the epidemiology of Primary Immunodeficiencies and how does that translate in clinical care. Rare Diseases and Orphan Drugs. 2014;1(4):25\u20137.","journal-title":"Rare Diseases and Orphan Drugs."},{"issue":"4","key":"688_CR36","doi-asserted-by":"publisher","first-page":"951-957.e11","DOI":"10.1016\/j.jaci.2012.06.021","volume":"130","author":"Richard L. Wasserman","year":"2012","unstructured":"Wasserman RL, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951\u20137.e11.","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"11","key":"688_CR37","doi-asserted-by":"publisher","first-page":"e49699","DOI":"10.1371\/journal.pone.0049699","volume":"7","author":"G Baio","year":"2012","unstructured":"Baio G, et al. Economic burden of human papillomavirus-related diseases in Italy. PLoS One. 2012;7(11):e49699.","journal-title":"PLoS One"},{"issue":"9","key":"688_CR38","first-page":"1610","volume":"19","author":"A Marcellusi","year":"2015","unstructured":"Marcellusi A, et al. The economic burden of HCV-induced diseases in Italy. A probabilistic cost of illness model. Eur Rev Med Pharmacol Sci. 2015;19(9):1610\u201320.","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"3","key":"688_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","volume":"27","author":"ER Stiehm","year":"2013","unstructured":"Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27(3):171\u20138.","journal-title":"Transfus Med Rev"},{"key":"688_CR40","unstructured":"Istituto Nazionale di Statistica. ISTAT. 2017 [cited 2017; Italian employment rate]. http:\/\/www.istat.it\/it\/ . Accessed 31 Jul 2018."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0688-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0688-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0688-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:30:16Z","timestamp":1720571416000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0688-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["688"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0688-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]},"assertion":[{"value":"6 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This analysis was funded by Baxalta SpA. The authors confirm that the paper is an accurate representation of the study results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Viti Raffaella, Marcellusi Andrea, Capone Alessandro, Matucci Andrea, Vultaggio Alessandra, Pignata Claudio, Spadaro Giuseppe, Vacca Angelo, Marasco Carolina, Agostini Carlo, and Mennini Francesco Saverio declare that there are no conflicts of interest regarding the publication of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}